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Risk Stratification With
Electrocardiographic-Gated
Dobutamine Stress Imaging
We read with interest the study by Navare et al. (1). We
congratulate the authors for the original contribution by showing
that the combination of function and perfusion assessment with
this technique improves risk stratification. We were, however,
concerned about the high event rate of 2.4% in patients with
normal perfusion and function. The investigators pointed to the
fact that inability to exercise is associated with adverse outcome
regardless of the results of stress testing, which has been confirmed
by previous studies (2). An important explanation would also be
the fact that many of the patients who have a contraindication for
vasodilator stress are likely to have dyspnea. The recent study by
Abidov et al. (3) as shown that dyspnea is associated with worse
survival among those with and without coronary artery disease
referred for nuclear stress testing.
Another major reason for the high event rate among patients with
normal perfusion in this study is the exceptionally high rate of failure
to achieve the target heart rate (33%), which is significantly higher
than what is reported with dobutamine myocardial perfusion imaging
in the U.S. (4) and Europe (5). Failure to achieve the target heart rate
was related to an adverse outcome, which reflects a reduced sensitivity
in that setting. The maximal achieved heart rate, dose, and frequency
of atropine administration were not provided to verify effectiveness of
the stress protocol. In their analysis of the subset of patients who
achieved the target heart rate, the annual hard event rate was 1.5%
among those with normal perfusion and function (1). However, the
range of follow-up was not provided. Survival curves showed that some
patients were followed for over 6 years. Because the curves tended to be
steeper late during follow-up in patients with normal studies, it is likely
that the event rate was lower than 1.5% in the first 2 years following the
stress test. It is to be emphasized that comparing these results with
exercise myocardial perfusion imaging studies that showed an event rate
of1% with normal perfusion should take into account the differences in
the maximal duration of follow-up and the fact that the target heart rate
was achieved more frequently in the exercise studies.
Therefore, we believe that dobutamine myocardial perfusion
imaging may still identify a lower-risk population within 2 years of
follow-up, when the target heart rate is achieved, with figures
closer to the reports from European centers in patients who do not
necessarily have a contraindication for vasodilator stress (6,7). The
flow heterogeneity obtained by high-dose dobutamine–atropine
stress was shown to be equal to that obtained by dipyridamole
(8,9). The relatively high event rate among patients with normal
perfusion in this study is likely due to the unique characteristics of
the study patients and the reduced sensitivity in the 33% of
patients who failed to achieve the target heart rate.
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REPLY
We appreciate the interest in our study by Elhendy et al. (1). They
raise a number of important issues, which are subsequently
addressed:
1. We share the concern that patients with normal perfusion
and function with dobutamine myocardial perfusion imag-
ing (MPI) have higher event rates than do those with similar
results after exercise MPI. A primary goal of our work was to
confirm or deny a previous report in a “high-risk population” in
which patients were selected for dobutamine stress only if they
were unable to undergo exercise or vasodilator stress. Our
results confirm those reported by Calnon et al. (2), and extend
the observation that, despite normal function, those with
normal perfusion still have higher event rates. We acknowl-
edge that when dobutamine MPI is used as a primary stressor
in an unselected population, a normal dobutamine MPI
identifies a low-risk population, and this was referred to in the
Discussion section of our study (3–5).
2. In the recent study by Abidov et al. (6), dyspnea was coded
only in patients who did not have chest pain as indication for
stress testing. In our study, 87% of patients had a chest pain
syndrome, 5% were preoperative, whereas only 8% had mis-
cellaneous (congestive heart failure, abnormal electrocardio-
gram, etc.) indications. Thus, the prevalence of dyspnea as an
isolated risk factor was small, and the contribution of dyspnea
alone toward the higher event rate was minimal.
3. With regards to achievement of target heart rate, few studies
have reported percentages. Hence, it is not clear whether the
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